

FORM PTO-1449		US Dept. of Commerce Patent and Trademark Office	ATTORNEY DOCKET NO. 4012-113 DIV2	SERIAL NO. 09/430,735
INFORMATION DISCLOSURE STATEMENT (use several sheets if necessary)			APPLICANT Ekwuribe et al.	GROUP 1639
			FILING DATE October 29, 1999	
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)				
CM	Pardridge, W.M., "Blood-Brain Barrier Peptide Transport and Peptide Drug Delivery to the Brain," Amer. Chem Soc. 1995: 265-296.			
CN	Pardridge, W.M., "CNS Drug Design Based on Principles of Blood-Brain Barrier Transport," J. Neurochem., 1998, 70 (5): 1781-1792.			
CO	Pardridge, W.M., "New Approaches to Drug Delivery Through the Blood-Brain Barrier," Trends in Biotechnology, 1994: 239-245.			
CP	Prokai-Tatrai, K., et al., "Brain-Targeted Delivery of a Leucine-Enkephalin Analogue by Retrometabolic Design," J. Med. Chem 39 (24).			
CQ	Ratner, R. E. et al., "Persistent Cutaneous Insulin Allergy Resulting from High-Molecular Weight Insulin Aggregates," Diabetes, 1990, 39: 728-733.			
CR	Robbins, D. C. et al., "Antibodies to Covalent Aggregates of Insulin in Blood of Insulin-Using Diabetic Patients," Diabetes, 1987, 36: 838-841.			
CS	Saffran, M. et al., "A New Approach to the Oral Administration of Insulin and Other Peptide Drugs," Science, 1986, 233: 1081-1084.			
CT	Sakaeda, T., et al., "Conjugation with L-Glutamic Acid for Brain Drug Delivery," Proceed. Intern. Symp. Control. Rel. Bioact. Mater., 1966, 23: 607-608.			
CU	Shashoua V.E., et al., "γ-Aminobutyric Acid Esters. 1. Synthesis, Brain Uptake, and Pharmacological Studies of Aliphatic and Steroid Esters of γ-Aminobutyric Acid," J. Med. Chem., 1984, 27 (5): 660-664.			
CV	Shashoua, V.E., et al., "N-Docosahexaenoyl, 3 Hydroxytyramine: A Dopaminergic Compound that Penetrates the Blood-Brain Barrier and Suppresses Appetite," Life Sciences, 58 (16): 1347-1354.			
CW	Sim, L., et al., "In vitro Autoradiography of Receptor-Activated G Proteins in Rat Brain by Agonist-stimulated Guanylyl 5'-[γ ³⁵ S]thio]-Triphosphate Binding," Proc. Natl. Acad. Sci., USA, 1995, 92: 7242-7246.			
CX	Terasaki, T., et al., "Oligopeptide Drug Delivery to the Brain," Amer. Chem. Soc. 1995: 297-316.			
CY	Tsuzuki, N., et al., "Rapid Communication. Adamantane as a Brain-Directed Drug Carrier for Poorly Absorbed Drug: Antinociceptive Effects of [D-Ala ²] Leu-Enkephalin Derivatives Conjugated with the 1-Adamantane Moiety," Biochemical Pharmacology, 1991, 41 (4): R5-R8.			
CZ	Wagner, J., et al., "Neuropharmacology of Endogenous Opioid Peptides," Psychopharmacology: The Fourth Generation of Progress, 1995: 519-529.			
DA	Weber, S.J., et al., "Distribution and Analgesia of [³ H][D-PEN ² , D-PEN ⁵] Enkephalin and Two Halogenated Analogs after Intravenous Administration," J. Pharm. Exper. Ther., 1991, 259: 1109-1112.			
DB	Weber, S.J., et al., "Whole Body and Brain Distribution of [³ H]Cyclic [D-PEN ² , D-PEN ⁵] Enkephalin after Intraperitoneal, Intravenous, Oral and Subcutaneous Administration," J. Pharm. Exper. Ther., 1992, 263: 1308-1316.			
Continue on Page				
Examiner B. C. C. S. A			DATE CONSIDERED skelton	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.				

FORM PTO-1449		US Dept. of Commerce Patent and Trademark Office		ATTORNEY DOCKET NO. 4012-113 DIV2		SERIAL NO. 09/430,735	
INFORMATION DISCLOSURE STATEMENT (use several sheets if necessary)				APPLICANT Ekwuribe et al.		RECEIVED DEC 14 1999 TECH CENTER 1800/2901	
				FILING DATE October 29, 1999			
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<i>[initials]</i>	AA	4,585,754	29 Apr. 1986	Meisner et al.	514	8	—
<i>[initials]</i>	AB	4,179,337	18 Dec. 1979	Davis et al.	435	181	—
<i>[initials]</i>	AC	4,003,792	18 Jan. 1977	Mill et al.	195	63	—
<i>[initials]</i>	AD	4,849,405	18 Jul. 1989	Ecanow	514	3	—
<i>[initials]</i>	AE	5,013,556	7 May 1991	Woodle et al.	424	450	—
<i>[initials]</i>	AF	4,963,367	16 Oct. 1990	Ecanow	424	485	—
<i>[initials]</i>	AG	4,044,196	23 Aug. 1977	Hüper et al.	536	271	—
<i>[initials]</i>	AH	4,717,566	5 Jan. 1988	Eckenhoff et al.	424	438	—
<i>[initials]</i>	AI	4,698,264	6 Oct. 1987	Steinke	428	402.2	—
<i>[initials]</i>	AJ	4,684,524	4 Aug. 1987	Eckenhoff et al.	424	469	—
<i>[initials]</i>	AK	4,410,547	18 Oct. 1983	Ueno et al.	424	317	—
<i>[initials]</i>	AL	3,256,153	14 Jun. 1966	Heimlich	167	82	—
<i>[initials]</i>	AM	4,935,246	19 Jun. 1990	Ahrens	424	490	—
<i>[initials]</i>	AN	4,797,288	10 Jan 1989	Sharma et al.	424	476	—
<i>[initials]</i>	AO	4,744,976	17 May 1988	Snipes et al.	424	408	—
<i>[initials]</i>	AP	5,055,304	8 Oct. 1991	Makino et al.	424	465	—
<i>[initials]</i>	AQ	5,055,300	8 Oct. 1991	Gupta	424	409	—
<i>[initials]</i>	AR	4,772,471	20 Sep. 1988	Vanlerberghe et al.	424	450	—
<i>[initials]</i>	AS	5,093,198	3 Mar. 1992	Speaker et al.	428	402.21	—
<i>[initials]</i>	AT	4,840,799	20 Jun. 1989	Appelgren et al.	424	493	—
<i>[initials]</i>	AU	4,622,392	11 Nov. 1986	Hong et al.	536	29	—
<i>[initials]</i>	AV	5,653,987	5 Aug. 1997	Modi et al.	424	400	—
<i>[initials]</i>	AW	5,792,834	11 Aug. 1998	Hakimi et al.	530	351	—
<i>[initials]</i>	AX	5,595,732	21 Jan. 1997	Hakimi et al.	424	85.7	—
<i>[initials]</i>	AY	5,539,063	23 Jul. 1996	Hakimi et al.	525	403	—
Continue on page 2							
EXAMINER B celsa						DATE CONSIDERED 5/2/03	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							

FORM PTO-1449		US Dept. of Commerce Patent and Trademark Office		ATTORNEY DOCKET NO. 4012-113 DIV2		SERIAL NO. 09/430,735	
INFORMATION DISCLOSURE STATEMENT (use several sheets if necessary)				APPLICANT Ekwuribe et al.			
				FILING DATE October 29, 1999		GROUP 1639	

EXAMINER INITIAL	PATENT NUMBER	ISSUE DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<i>[initials]</i>	AZ	5,559,213	Hakimi et al.	530	351	—
<i>[initials]</i>	BA	5,747,646	Hakimi et al.	530	351	—
<i>[initials]</i>	BB	5,286,637	Veronese et al.	530	183	—
<i>[initials]</i>	BC	5,631,263	Portoghese et al.	530	279	—
<i>[initials]</i>	BD	5,602,099	Schiller	530	18	—
<i>[initials]</i>	BE	5,545,719	Shashoua et al.	530	345	—
<i>[initials]</i>	BF	5,641,861	Dooley et al.	530	329	—
<i>[initials]</i>	BG	5,663,295	Moreau et al.	530	330	—
<i>[initials]</i>	BH	5,786,447	Schiller et al.	530	307	—
<i>[initials]</i>	BI	4,939,174	Shashoua	530	549	—
<i>[initials]</i>	BJ	5,932,462	Harris et al.	435	188	—

FOREIGN PATENT DOCUMENTS							
DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
					YES	NO	
						X	


OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)		
<i>[initials]</i>	BK	Alyautdin, R.N., "Delivery of Loperamide Across the Blood-Brain Barrier with Polysorbate 80-Coated Polybutylcyanoacrylate Nanoparticles," Pharm. Res. J., 1997, 14: 325-328.
	BL	Aoshima, M. et al., "N ⁴ -Behenoyl-1-β-D-Arabinofuranosylcytosine as a Potential New Antitumor Agent," Cancer Research, 1977, 37: 2481-2486.
	BM	Banting, R. G., et al., "Pancreatic Extracts in the Treatment of Diabetes Mellitus," The Canadian Med. Assoc. J. 1922, 12: 141-146.
	BN	Baker, D. C. et al., "Prodrugs of 9-β-D-Arabinofuranosyladenine. 1. Synthesis and Evaluation of Some 5'-(O-Acyl) Derivatives," J. Med. Chem., 1978, 21(12): 1218-1221.
	BO	Banks, W.A., et al., "Passage of Peptides Across the Blood-Brain Barrier: Pathophysiological Perspectives," Life Sciences, 1996, 59 (23), 1923-1943.
	BP	Boccu, E. et al., "Pharmacokinetic Properties of Polyethylene Glycol Derivatized Superoxide Dismutase," Pharm. Res. Comm., 1982, 14: 11-120.
<i>[initials]</i>	BQ	Bodor, N., et al., "A Strategy for Delivering Peptides into the Central Nervous System by Sequential Metabolism," Science, 1992, 257, 1698-1702.


Continued on page 3

Examiner <i>B. CuyA</i>	DATE CONSIDERED <i>5/2/03</i>
--------------------------------	--------------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

FORM PTO-1449		US Dept. of Commerce Patent and Trademark Office	ATTORNEY DOCKET NO. 4012-113 DIV2	SERIAL NO. 09/430,735
INFORMATION DISCLOSURE STATEMENT (use several sheets if necessary)			APPLICANT Ekwuribe et al.	GROUP 1639
			FILING DATE October 29, 1999	



	BR	Bodor, N., et al., "Molecular Packaging. Peptide Delivery to the Central Nervous System by Sequential Metabolism," Amer. Chem. Soc., 1995: 317-337.
	BS	Brange, J. et al., "Chemical Stability of Insulin. 1. Hydrolytic Degradation During Storage of Pharmaceutical Preparations," Pharm. Res., 1992, 9 (6): 715-726.
	BT	Brange, J. et al., "Chemical Stability of Insulin. 2. Formation of Higher Molecular Weight Transformation Products During Storage of Pharmaceutical Preparations," Pharm. Res., 1992, 9 (6): 727-734.
	BU	Brewster, M.E., et al., "Effect of Molecular Manipulation on the Estrogenic Activity of a Brain-Targeting Estradiol Chemical Delivery System," J. Med. Chem., 1994, 37: 4237-4244
	BV	Brewster, M.E., et al., "Efficacy of a 3-Substituted Versus 17-Substituted Chemical Delivery System for Estradiol Brain Targeting," J. Pharm. Sci., 1994: A-E.
	BW	Brewster, M., et al., "Tissue Distribution of LY231617, an Antioxidant with Neuroprotectant Activity, in the Rat," J. Pharm. Studies, 1995, 84 (7): 791-793.
	BX	Conradi, R.A., et al., "The Influence of Peptide Structure on Transport Across Caco-2 Cells," Pharm. Res., 1991, 8 (12): 1453-1459.
	BY	Chen, C., et al., "Extensive Biliary Excretion of the Model Opioid Peptide [D-PEN ^{2,5}] Enkephalin in Rats," Pharm. Res. J., 14: 345-350.
	BZ	Chiou, G.C.Y., et al., "Systemic Delivery of Enkephalin Peptide through Eyes," Life Sciences, 1988, 43: 509-514.
	CA	Chun, W., et al., "Transmucosal Delivery of Methionine Enkephalin. I: Solution Stability and Kinetics of Degradation in Various Rabbit Mucosa Extracts," J. Pharm.Sci., 1993, 82 (4): 373-378.
	CB	Fix, J.A., "Oral Controlled Release Technology for Peptides: Status and Future Prospects," Pharm. Res., 1996, 13 (12): 1760-1763.
	CC	Gibson, A.M., et al., "Specificity of Action of Human Brain Alanyl Aminopeptidase on Leu-Enkephalin and Dynorphin-Related Peptides," Neuropeptides, 1989, 13: 259-262.
	CD	Gish, D. T. et al., "Nucleic Acids. 11. Synthesis of 5'-Esters of 1-β-D-Arabinofuranosylcytosine Possessing Antileukemic and Immunosuppressive Activity," J. Med. Chem., 1971, 14(12): 1159-1162.
	CE	Hong, C. I. et al., "Nucleoside Conjugates. 7. Synthesis and Antitumor Activity of 1-β-D-Arabinofuranosylcytosine Conjugates of Ether Lipids," J. Med. Chem., 1986, 29: 2038-2044.
	CF	Horvat, J., et al., "Synthesis and Biological Activity of [Leu ⁵] Enkephalin Derivatives Containing D-Glucose," J. Peptide Protein Res., 1988, 31: 499-507.
	CG	Hostetler, K. Y. et al., "Synthesis and Antiretroviral Activity of Phospholipid Analogs of Azidothymidine and Other Antiviral Nucleosides," The Journal of Biological Chemistry, 1990, 265(11): 6112-6117.
CH	Kroll, R.A., et al., "Outwitting the Blood-Brain Barrier for Therapeutic Purposes: Osmotic Opening and Other Means," 1998 Neurosurgery, 42 (5): 1083-1100.	
CI	Maislos, M. et al., "The Source of the Circulating Aggregate of Insulin in Type I Diabetic Patients is Therapeutic Insulin," J. Clin. Invest., 1986, 77: 717-723.	
CJ	Mosnaim, A.D., et al., "Studies of the in Vitro Human Plasma Degradation of Methionine-Enkephalin," Gen. Pharmac., 1988, 19 (5): 729-733.	
CK	Nestor, J., "Improved Duration of Action of Peptide Drugs," Amer. Chem Soc. 1995: 449-471.	
CL	Oka, K. et al., "Enhanced Intestinal Absorption of a Hydrophobic Polymer-Conjugated Protein Drug, Smanacs, in an Oily Formulation," Pharm. Res., 1990, 7 (8): 852-855.	

Continue on Page 4

Examiner B CAGA	DATE CONSIDERED 5/21/03
--------------------	----------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

